Plus Therapeutics Inc

Cerenome, Inc. (Nasdaq: CNSY), formerly Plus Therapeutics, is a central nervous system (CNS) oncology company. It combines commercial precision diagnostics, targeted radiopharmaceuticals and a data/artificial intelligence platform.

**Diagnostics (CNSide).** Through its wholly owned subsidiary CNSide Diagnostics, LLC, the company sells the CNSide CSF Assay Platform. These laboratory-developed tests analyze cerebrospinal fluid to detect, characterize and monitor tumor cells that have spread to the CNS, especially leptomeningeal metastases (LM).
- The menu covers tumor cell enumeration plus CNSide CSF Molecular Profile tests, which provide DNA and RNA profiling for solid tumors and hematologic malignancies.
- The business began generating net diagnostic revenue in Q3 2026.
- Contracted payer coverage reaches about 190 million covered lives, including Aetna, Florida Blue and several Blue Cross plans; Medicare reimbursement is targeted for 1H 2027.

**Therapeutics (REYOBIQ).** The lead therapeutic is REYOBIQ (rhenium Re186 obisbemeda), an injectable radiotherapy that delivers targeted high-dose radiation directly to CNS tumors. It is in clinical trials for:
- Leptomeningeal metastases (ReSPECT-LM), funded by a [USD:17,600,000] CPRIT grant.
- Recurrent glioblastoma (ReSPECT-GBM), supported by the National Cancer Institute; Phase 2 enrollment is complete.
- Pediatric brain cancer (ReSPECT-PBC), supported by a Department of Defense grant.

**Data and AI.** The company is building a platform that integrates diagnostic, molecular, imaging and clinical data to support precision oncology.

**Financing.** Operations are funded through equity sales, grants and a recently closed senior secured royalty-based financing facility. Updated Nov 13, 2026